Tse Wen Chang, internationally recognized as one of the greatest contributors to the biotech field, and founder, CEO, and president of Immunwork, provides insights into the company’s ground-breaking T-E™ pharmaceuticals, which combine both targeting (T) and effector (E) moieties to form a new class of innovative drugs displaying significantly enhanced efficacy and safety profiles.
As one of the most reputed scientists in the immunology and antibody fields, could you introduce yourself and tell us some of your main achievements on both the business and scientific side?
"Most oncology drugs currently available unfortunately display low response rates (usually below 50 percent) and severe side effects."
